The objective of the New Opportunities is to deliver a successful portfolio of new treatment options from areas outside our current Therapy Area focus.
The cross functional New Opportunities team identifies, evaluates and secures new business, which will enhance the value and performance of AstraZeneca and deliver new treatments to patients in areas of unmet medical need.
Key Areas of partnering interest
- Ophthalmology
- Osteoporosis and bone disorders
- Wound-healing (including diabetic ulcers)
- Cachexia, muscle-wasting and dysfunction
- Novel delivery systems applicable to our diseases of current interest
Contact information
jenny.horsfield@astrazeneca.com
paul.fletcher@astrazeneca.com
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At Nov 21, 2009 9:33 AM GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
